Mw Wegovy's Prices Are Going Down, But They Are 'Wildly Different' - And Confusing

What Happened?

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. 

These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Immuno-Oncology company Natera jumped 2.9%. Is now the time to buy Natera? Access our full analysis report here, it’s free for active Edge members.
• Healthcare Technology for Patients company GoodRx jumped 3%. Is now the time to buy GoodRx? Access our full analysis report here, it’s free for active Edge members.
• Research Tools & Consumables company Bio-Techne jumped 3.1%. Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Bio-Techne (TECH)

Bio-Techne’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock gained 4.5% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

Bio-Techne is down 11.1% since the beginning of the year, and at $63.55 per share, it is trading 19.3% below its 52-week high of $78.75 from January 2025. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at an investment worth $842.42.

What Happened?

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Health Insurance Providers company Clover Health jumped 5.3%. Is now the time to buy Clover Health? Access our full analysis report here, it’s free for active Edge members.
• Healthcare Technology for Patients company GoodRx jumped 4.7%. Is now the time to buy GoodRx? Access our full analysis report here, it’s free for active Edge members.
• Therapeutics company Moderna jumped 5.1%. Is now the time to buy Moderna? Access our full analysis report here, it’s free for active Edge members.
• Drug Development Inputs & Services company UFP Technologies jumped 5.3%. Is now the time to buy UFP Technologies? Access our full analysis report here, it’s free for active Edge members.
• Patient Monitoring company Masimo jumped 4.4%. Is now the time to buy Masimo? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Clover Health (CLOV)

Clover Health’s shares are extremely volatile and have had 35 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 15 days ago when the stock dropped 8.4% on the news that the stock's negative momentum continued as the company reported disappointing third-quarter 2025 financial results and cut its full-year profitability forecast. 

Although revenue grew by 50.1% year-over-year to $496.7 million, beating expectations due to strong membership growth, the company's profitability raised concerns. Clover Health posted a net loss of $0.05 per share, which missed analyst estimates. Management pointed to higher-than-expected medical costs and increased healthcare usage from a surge of new members as reasons for the weaker results. More importantly, the company significantly lowered its full-year adjusted EBITDA guidance to a range of $15 million to $30 million, down from the previous forecast of $50 million to $70 million. This weaker outlook overshadowed the top-line growth, signaling to investors that near-term margins and profits were under pressure.

Clover Health is down 27.5% since the beginning of the year, and at $2.27 per share, it is trading 52.9% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health’s shares 5 years ago would now be looking at an investment worth $226.77.